Opus Genetics, Inc. IRD
Opus Genetics, Inc. (the "Company," "Opus," "we," "us," or "our") is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent
blindness in patients with inherited retinal diseases ("IRDs"), and other types of therapies for additional ophthalmic disorders.
In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution.
In January 2020, Ocuphire Pharma, Inc. obtained from Apexian Pharmaceuticals, Inc. certain rights to its Ref-1 inhibitor program, including APX3330.
Last close
3.47
2026-10-23
Market cap
$288.7M
2026-06-30 share count
52-week range
1.70 - 7.07
Valuation FY2025 figures against the last close
P/S20.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.80
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589.0K | $0 | $3.0M | — | — | — |
| R&D | — | — | — | — | — | — | $5.5M | $13.1M | $10.7M | $10.1M |
| SG&A | $22.0M | $18.2M | $12.0M | $7.3M | $8.1M | $2.8M | $1.8M | $7.4M | $6.6M | $6.3M |
| Total operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M | $20.0M | $4.2M | $20.5M | $17.4M | $16.4M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M | -$20.0M | -$4.2M | -$20.5M | -$17.4M | -$16.4M |
| Interest expense | $129.0K | $0 | $0 | $9.0K | $2.0K | $6.8M | $1.4M | — | — | — |
| Pre-tax income | -$49.6M | -$57.5M | -$10.0M | $18.2M | -$56.7M | -$24.6M | -$6.2M | — | — | — |
| Income tax | $0 | $0 | $12.0K | $315.0K | $0 | $0 | $0 | — | — | — |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M | -$24.6M | -$6.2M | -$14.4M | -$25.3M | -$9.3M |
| EPS, basic | -0.80 | -2.15 | -0.46 | 0.90 | -3.82 | -5.28 | — | — | — | — |
| EPS, diluted | -0.80 | -2.15 | -0.46 | 0.87 | -3.82 | -5.28 | -2.17 | -5.25 | -0.92 | -0.43 |
| Shares, diluted (wtd. avg.) | 62.2M | 26.7M | 21.6M | 20.6M | 14.9M | 4.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M | $16.4M | $1.5M | $451.0K | $8.9M | $11.6M |
| Short-term investments | $0 | $2.0K | $15.0K | $49.0K | $219.0K | $0 | — | — | — | — |
| Receivables | $2.0M | $3.6M | $926.0K | $1.3M | $0 | — | — | — | — | — |
| Total current assets | $50.0M | $36.6M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M | $15.9M | $28.1M | $20.9M |
| Property, plant and equipment | $199.0K | $252.0K | $0 | $6.0K | $10.0K | $14.0K | $22.0K | $112.5K | $121.5K | $88.7K |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M | $17.7M | $1.8M | $16.0M | $28.3M | $21.0M |
| Accounts payable | $3.3M | $3.1M | $2.2M | $1.1M | $1.6M | $1.2M | $342.0K | $3.2M | $3.2M | $1.9M |
| Short-term debt | — | — | — | $0 | $600.0K | $0 | — | — | — | — |
| Total current liabilities | $7.8M | $11.3M | $4.0M | $2.8M | $3.9M | $3.2M | $9.3M | $3.2M | — | — |
| Long-term debt | $1.1M | $0 | — | — | — | — | — | — | — | — |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M | $31.1M | $9.3M | $5.5M | $11.5M | $4.0M |
| Retained earnings | -$188.6M | -$139.0M | -$81.5M | -$71.5M | -$89.4M | -$32.7M | -$8.1M | -$154.7M | -$140.3M | -$115.0M |
| Total equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | -$13.5M | -$7.6M | -$1.7M | $16.8M | $17.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M | -$6.8M | -$3.6M | -$18.8M | -$15.4M | -$13.2M |
| Depreciation and amortisation | $53.0K | $10.0K | $6.0K | $4.0K | $4.0K | $8.0K | $3.0K | — | — | — |
| Stock-based compensation | $3.4M | $3.4M | $3.5M | $1.8M | $1.9M | $1.5M | $308.0K | $1.2M | $1.0M | $1.4M |
| Capital expenditure | — | — | — | — | — | $0 | $25.0K | — | — | — |
| Investing cash flow | $0 | $1.2M | $0 | $0 | -$100.0K | $539.0K | -$25.0K | $11.9M | -$9.4M | $4.5M |
| Financing cash flow | $50.0M | $4.2M | $9.0M | $3.8M | $27.6M | $21.1M | $4.7M | $6.8M | $22.1M | $10.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-009247.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3.0M | $0 | $589.0K | $39.9M | $19.0M | $11.0M | $14.2M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$9.3M | -$25.3M | -$14.4M | -$6.2M | -$24.6M | -$56.7M | $17.9M | -$10.0M | -$57.5M | -$49.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |